Genotype-phenotype correlation of maternally inherited disorders due to mutations in mitochondrial DNA

Taiwanese Journal of Obstetrics and Gynecology

Volumn 45, Issue 3, 2006, Pages 201-207

  Thajeb, Peterus ^a,b,c,f   Dai, Daofu ^d   Chiang, Ming Fu ^a   Shyu, Woei Cherng ^e  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e TZU CHI UNIVERSITY   (Taiwan)

^f NONE   (Taiwan)

Author keywords

Encephalopathy; Epilepsy; Mitochondrial disease; Mitochondrial DNA; Mutation; Myopathy; Oxidative phosphorylation; OXPHOS disease

Indexed keywords

MITOCHONDRIAL DNA;

ARTICLE; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; CORRELATIONAL STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; FEMALE; GENOTYPE; HISTOPATHOLOGY; HUMAN; INHERITANCE; KEARNS SAYRE SYNDROME; LEBER HEREDITARY OPTIC NEUROPATHY; LEIGH DISEASE; MATERNAL CARE; MELAS SYNDROME; MERRF SYNDROME; MNGIE SYNDROME; MOLECULAR MECHANICS; MUTATION; MYOPATHY; NARP SYNDROME; PHENOTYPE;

EID: 33749488987     PISSN: 10284559     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1028-4559(09)60225-4     Document Type: Review

References (86)

1. Nass MM, Nass S. Intramitochondrial fibers with DNA characteristics. I. Fixation and electron staining reactions. J Cell Biol 1963;19:593-611.
2. Anderson S, Bankier AT, Barrell BG, et al. Sequence and organization of human mitochondrial genome. Nature 1981;290:457-65.
3. Shoffner JM, Wallace DC. Oxidative phosphorylation diseases. Disorders of two genomes. In: Harris H, Hirschhorn K, eds. Advances in Human Genetics. Plenum, 1990;19:267-330.
4. Schapira AHV, Cooper JM, Morgan-Hughes JA, et al. Mitochondrial myopathy with a defect of mitochondrial protein transport. N Engl J Med 1990;323:37.
5. Moraes CT, Shanske S, Tritschler HJ, et al. MtDNA depletion with variable tissue expression: a novel genetic abnormality in mitochondrial disease. Am J Hum Genet 1991;48:492-501.
6. nd edition. New York: McGraw-Hill, 1994:1622-3.
7. DiMauro S, Tonin P, Servidei S. Metabolic myopathies. In: Rowland LP, DiMauro S, eds. Myopathies, Handbook of Clinical Neurology. Elsevier Science, 1992;18:496-7.
8. th edition. London: Churchill Livingstone, 2002;1:299-409.
9. Graf WD, Sumi SM, Copass MK, et al. Phenotypic heterogeneity in families with the myoclonic epilepsy and ragged-red fiber disease point mutation in mitochondrial DNA. Ann Neurol 1993;33:640-45.
10. Luft R, Ikkos D, Palmieri G, Emster L, Afzelius B. A case of severe hypermetabolism of nonthyroid origin with a defect in the maintenance of mitochondrial respiratory control: a correlated clinical, biochemical, and morphological study. J Clin Invest 1962;41:1776-804.
11. Engel WK, Cunningham GC. Rapid examination of muscle tissue: an improved trichrome method for fresh-frozen biopsy sections. Neurology 1963;13:919-23.
12. Shy GM, Gonatas NK. Human myopathy with giant abnormal mitochondria. Science 1964;145:493-6.
13. Shy GM, Gonatas NK, Perez M. Two childhood myopathies with abnormal mitochondria: I. Megoconial myopathy. II. Pleoconial myopathy. Brain 1966;89:133-58.
14. Shapira Y, Harel S, Russell A. Mitochondrial encephalomyopathies: a group of neuromuscular disorders with defects in oxidative metabolism. Isr J Med Sci 1977;13:161-4.
15. Thajeb P, Lee HC, Pang CY, Jeng CM, Huang SF, Wei YH. Phenotypic heterogeneity in a Chinese family with mitochondrial disease and A3243G mutation of mitochondrial DNA. Chin Med J (Taipei) 2000;63:71-6.
16. th edition. New York: McGraw-Hill, 2001:2425-509.
17. Holt IJ, Harding AE, Morgan-Hughes JA. Deletions of muscle mitochondrial DNA in patients with mitochondrial myopathies. Nature 1988;331:717.
18. Schon EA, Rizzuto R, Moraes CT, Nakase H, Zeviani M, DiMauro S. A direct repeat is a hotspot for large-scale deletion of human mitochondrial DNA. Science 1989;244:346-9.
19. Moraes CT, DiMauro S, Zeviani M, et al. Mitochondrial DNA deletions in progressive external ophthalmoplegia and Kearns-Sayre syndrome. N Engl J Med 1989;320:1293-9.
20. Shoffner JM, Lott MT, Voljavec AS, Soueidan SA, Costigan DA, Wallace DC. Spontaneous Kearns-Sayre/chronic external ophthalmoplegia plus syndrome associated with a mitochondrial DNA deletion: a slip-replication model and metabolic therapy. Proc Natl Acad Sci USA 1989;86:7952-6.
21. Lys mutation. Cell 1990;61:931-7.
22. Hammans SR, Sweeney MG, Brockington M, et al. The mitochondrial DNA transfer RNA(Lys)A to G(3243) mutation and the syndrome of myoclonic epilepsy with ragged-red fibers (MERRF). Relationship of clinical phenotype to proportion of mutant mitochondrial DNA. Brain 1993;116:617-32.
23. Hammans SR, Sweeney MG, Hanna MG, Brockington M, Morgan-Hughes JA, Harding AE. The mitochondrial DNA transfer RNALeu(UUR) A to G(3243) mutation. A clinical and genetic study. Brain 1995;118:721-34.
24. Chinnery PF, Howell N, Lightowlers RN, Turnbull DM. Molecular pathology of MELAS and MERRF. The relationship between mutation load and clinical phenotypes. Brain 1997;120:1713-21.
25. Tzen CY, Thajeb P, Wu TY, Chen SC. MELAS with point mutations involving tRNALeu (A3243G) and tRNAGlu (14693G). Muscle Nerve 2003;28:575-81.
26. Thajeb P, Ma YS, Tzen CY, Chuang CK, Wu TY, Chen SC, Wei YH. Oculopharyngeal somatic myopathy in a patient with a novel large-scale 3,399 bp deletion and a homoplasmic T5814C transition of the mitochondrial DNA. Clin Neurol Neurosurg 2006;108:407-10.
27. Pavlakis SG, Phillips PC, DiMauro S, deVivo DC, Rowland LP. Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes: a distinctive clinical syndrome. Ann Neurol 1984;16:481-8.
28. Ciafaloni E, Ricci E, Shanske S, et al. MELAS: clinical features, biochemistry, and molecular genetics. Ann Neurol 1992;31:391-8.
29. Abe K. Cerebral lactic acidosis correlates with neurological impairment in MELAS. Neurology 2004;63:2458.
30. Thajeb P, Huang KM, Chi EY, Shih CC, Su ML, Huang JS. Koshevnikov syndrome in a patient with MELAS plus syndrome: electron microscopic and neuroimage studies. Chin Med J (Taipei) 1997;110:726-30.
31. Finsterer J, Kopsa W. Basal ganglia calcification in mitochondrial disorders. Metab Brain Dis 2005;20:219-26.
32. Parry A, Matthews PM. Roles for imaging in understanding the pathophysiology, clinical evaluation, and management of patients with mitochondrial disease. J Neuroimaging 2003;13:293-302.
33. Apostolova LG, White M, Moore SA, Davis PH. Deep white matter pathologic features in watershed regions: a novel pattern of central nervous system involvement in MELAS. Arch Neurol 2005;62:1154-6.
34. Lerman-Sagie T, Leshinsky-Silver E, Watemberg N, Luckman Y, Lev D. White matter involvement in mitochondrial diseases. Mol Genet Metab 2005;84:127-36.
35. McFarland R, Taylor RW, Turnbull DM. The neurology of mitochondrial DNA disease. Lancet Neurology 2002;1:343-51.
36. Peng NJ, Liu RS, Li JY, et al. Increased cerebral blood flow in MELAS shown by Tc-99m HMPAO brain SPECT. Neuroradiology 2000;42:26-29.
37. Thajeb P, Wu MC, Shih BF, Tzen CY, Chiang MF, Yuan RY. Brain SPECT studies in patients with A3243G mutation of the mitochondrial DNA. Ann N Y Acad Sci 2005;1042:48-54.
38. Goto Y, Nonaka I, Horai S. A mutation in the tRNA (Leu) (UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature 1990;348:651-3.
39. Fang W, Huang CC, Lee CC, et al. Ophthalmologic manifestations in MELAS syndrome. Arch Neurol 1993;50:977-80.
40. Macmillan C, Lach B, Shoubridge EA. Variable distribution of mutant mitochondrial DNAs tRNA(Leu[3243]) in tissues of symptomatic relatives with MELAS: the role of mitotic segregation. Neurology 1993;43:1586-90.
41. Liou CW, Huang CC, Chee EC, et al. MELAS syndrome correlation between clinical features and molecular genetic analysis. Acta Neurol Scand 1994;90:354-9.
42. Zhang Y, Li JF, Wang FY, Li CX. The study of A3243G and G13513A mitochondria DNA point mutation in patients with cerebral infarction. Chin Med J (Beijing) 2001;114:129-35.
43. Tokunago M, Mita S, Sakuta R, Nonaka I, Araki S. Increased mitochondrial DNA in blood vessels and ragged-red fibers in mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS). Ann Neurol 1993;33:275-80.
44. Shoffner JM, Wallace DC. Oxidative phosphorylation diseases. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Basis of Inherited Disease. New York: McGraw-Hill, 1995:1535-609.
45. Kobayashi Y, Ichihashi K, Ohta S, et al. The mutant mitochondrial genes in mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) were selectively amplified through generations. J Inherit Metab Dis 1992;15:803-8.
46. Silvestri G, Ciafaloni E, Santorelli FM, et al. Clinical features associated with the A to G transition at nucleotide 8344 of mtDNA ("MERRF mutation"). Neurology 1993;43:1200-6.
47. Tanno Y, Yoneda M, Tanaka K, et al. Uniform tissue distribution of tRNA(Lys) mutation in mitochondrial DNA in MERRF patients. Neurology 1993;43:1198-200.
48. Servidei S. Mitochondrial encephalomyopathies: gene mutation. Neuromuscul Disord 2004;14:107-16.
49. DiMauro S, Gurgel-Giannetti J. The expanding phenotype of mitochondrial myopathy. Curr Opin Neurol 2005;18:538-42.
50. Hsu CC, Chuang YH, Tsai JL, et al. CPEO and carnitine deficiency overlapping in MELAS syndrome. Acta Neurol Scand 1995;92:252-5.
51. Kearns TP, Sayre GP. Retinitis pigmentosa, external ophthalmoplegia and complete heart block. Ophthalmology 1958;60:280-9.
52. Seneca S, Verhelst H, deMeirleir L, et al. A new mitochondrial point mutation in the transfer RNA(Leu) gene in a patient with a clinical phenotype resembling Kearns-Sayre syndrome. Arch Neurol 2001;58:1113-8.
53. Moraes CT, Zeviani M, Schon EA, Hickman RO, Vlcek BW, DiMauro S. Mitochondrial DNA deletion in a girl with manifestations of Kearns-Sayre and Lowe syndromes: an example of phenotypic mimicry? Am J Med Genet 1991;41:301-5.
54. Leigh D. Subacute necrotizing encephalomyelopathy in an infant. J Neurol Neurosurg Psychiatry 1951;14:216-21.
55. Christensen E, Melchior JC, Plum P. Infantile chronic necrotizing encephalopathy. Acta Paediatr 1963;52:304-12.
56. Pincus JH. Subacute necrotizing encephalomyelopathy (Leigh's disease): a consideration of clinical features and etiology. Dev Med Child Neurol 1972;14:87-101.
57. Sipe JC. Leigh's syndrome: the adult form of subacute necrotizing encephalomyelopathy with predilection for the brainstem. Neurology 1973;23:1030-8.
58. Hommes FA, Polman HA, Reerink JD. Leigh's encephalomyelopathy: an inborn error of gluconeogenesis. Arch Dis Child 1968;43:423-6.
59. Van Maldergem L, Trijbels F, DiMauro S, et al. Co-enzyme Q-responsive Leigh's encephalopathy in two sisters. Ann Neurol 2002;52:750-4.
60. Mattiazzi M, Vijayvergiya C, Gajewski CD, et al. The mtDNA T8993G (NARP) mutation results in an impairment of oxidative phosphorylation that can be improved byantioxidants. Hum Mol Genet 2004;13:869-79.
61. Wilson CJ, Wood NW, Leonard JV, Surtees R, Rahman S. Mitochondrial DNA point mutation T9176C in Leigh syndrome. J Child Neurol 2000;15:830-3.
62. Jiang YW, Qin J, Yuan Y, Qi Y, Wu XR. Neuropathologic and clinical features in eight Chinese patients with Leigh disease. J Child Neurol 2002;17:450-2.
63. Lev D, Yanoov-Sharav M, Watemberg N, Leshinsky-Silver E, Lerman-Sagie T. White matter abnormalities in Leber's hereditary optic neuropathy due to the 3460 mitochondrial DNA mutation. Eur J Paediatr Neurol 2002;6:121-3.
64. Morimoto N, Nagano I, Deguchi K, et al. Leber hereditary optic neuropathy with chorea and dementia resembling Huntington disease. Neurology 2004;63:2451-2.
65. Leonard JV, Schapira AHV. Mitochondrial respiratory chain disorders I: mitochondrial DNA defects. Lancet 2000;355:299-304.
66. Finsterer J, Jarius C, Eichberger, Jaksch M. Phenotype variability in 130 adult patients with respiratory chain disorder. J Inher Metab Dis 2001;24:560-76.
67. Man PY, Turnbull DM, Chinnery PF. Leber hereditary optic neuropathy. J Med Genet 2002;39:162-9.
68. Howell N, Miller NR, Mackey DA, Arnold A, Herrnstadt C, Williams IM, Kubacka I. Lightning strikes twice: Leber hereditary optic neuropathy families with two pathogenic mtDNA mutations. J Neuroophthalmol 2002;22:262-9.
69. Valentino ML, Barboni P, Ghelli A, et al. The ND1 gene of complex 1 is a mutational hotspot for Leber's hereditary optic neuropathy. Ann Neurol 2004;56:631-41.
70. Lodi R, Carelli V, Cortelli P, et al. Phosphorous MR spectroscopy shows a tissue specific in vivo distribution of biochemical expression of the G3460A mutation in Leber's hereditary optic neuropathy. J Neurol Neurosurg Psychiatry 2002;72:805-7.
71. Hirano M, Silvestri G, Blake DM, et al. Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): clinical, biochemical, and genetic features of an autosomal recessive mitochondrial disorder. Neurology 1994;44:721-7.
72. Nishino I, Spinazzola A, Hirano M. Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder. Science 1999;283:689-92.
73. Said G, Lacroix C, Plante-Bordeneuve V, et al. Clinicopathological aspects of the neuropathy of neurogastrointestinal encephalomyopathy (MNGIE) in four patients including two with a Charcot-Marie-Tooth presentation. J Neurol 2005;252:655-62.
74. Nishigaki Y, Marti R, Hirano M. ND5 is a hotspot for multiple atypical mitochondrial DNA deletions in mitochondrial neurogastrointestinal encephalomyopathy. Hum Mol Genet 2004;13:91-101.
75. Vissing J, Ravn K, Danielsen ER, et al. Multiple mtDNA deletions with features of MNGIE. Neurology 2002;59:926-9.
76. McFarland R, Taylor RW, Turnbull DM. The neurology of mitochondrial DNA disease. Lancet Neurology 2002;1:343-51.
77. Zeviani M, Gellera C, Antozzi C, et al. Maternally inherited myopathy and cardiomyopathy: association with mutation in mitochondrial DNA tRNA (Leu) (UUR). Lancet 1991;338:143-7.
78. Dalakas MC, Illa I, Pezeshkpour GH, et al. Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med 1990;322:1098.
79. Campos Y, Martin MA, Lorenzo G, Aparicio M, Cabello A, Arenas J. Sporadic ME/MELAS overlap syndrome associated with the 3243 tRNA(Leu(UUR)) mutation of mitochondrial DNA. Muscle Nerve 1996;19:187-90.
80. Pulkes T, Eunson L, Patterson V, et al. The mitochondrial DNA G13513A transition in ND5 is associated with LHON/MELAS overlap syndrome and may be a frequent cause of MELAS. Ann Neurol 1999;46:916-9.
81. Crimi M, Galbiati S, Moroni I, et al. A missense mutation in the mitochondrial ND5 gene associated with a Leigh-MELAS overlap syndrome. Neurology 2003;60:1857-61.
82. Mancuso M, Ferraris S, Pancrudo J, et al. New DGK gene mutations in the hepatocerebral form of mitochondrial DNA depletion syndrome. Arch Neurol 2005;62:745-7.
83. Ciafaloni E, Ricci E, Servidei S, et al. Widespread tissue distribution of a tRNALeu(UUR) mutation in the mitochondrial DNA of a patient with MELAS syndrome. Neurology 1991;41:1663-4.
84. Shiraiwa N, Ishii A, Iwamoto H, Mizusawa H, Kagawa Y, Ohta S. Content of mutant mitochondrial DNA and organ dysfunction in a patient with a MELAS subgroup of mitochondrial encephalomyopathies. J Neurol Sci 1993;120:174-9.
85. Tanno Y, Yoneda M, Tanaka K, et al. Quantitation of heteroplasmy of mitochondrial tRNA(Leu(UUR)) gene using PCR-SSCP. Muscle Nerve 1995;18:1390-7.
86. Holt IJ, Harding AE, Petty PK, Morgan-Hughes JA. A new mitochondrial disease associated with mitochondrial DNA heteroplasmy. Am J Hum Genet 1990;46:428-33.